BrightAccountsProduction v1.0.0 v1.0.0 2024-02-01 The company was not dormant during the period The company was trading for the entire period Unaudited Accounts Specialist medical practice activities
Post-graduate education 28 October 2025 0 0 11748092 2025-01-31 11748092 2024-01-31 11748092 2023-01-31 11748092 2024-02-01 2025-01-31 11748092 2023-02-01 2024-01-31 11748092 uk-bus:PrivateLimitedCompanyLtd 2024-02-01 2025-01-31 11748092 uk-curr:PoundSterling 2024-02-01 2025-01-31 11748092 uk-bus:FullAccounts 2024-02-01 2025-01-31 11748092 uk-bus:Director1 2024-02-01 2025-01-31 11748092 uk-bus:Director2 2024-02-01 2025-01-31 11748092 uk-bus:RegisteredOffice 2024-02-01 2025-01-31 11748092 uk-bus:Agent1 2024-02-01 2025-01-31 11748092 uk-core:ShareCapital 2025-01-31 11748092 uk-core:ShareCapital 2024-01-31 11748092 uk-core:RetainedEarningsAccumulatedLosses 2025-01-31 11748092 uk-core:RetainedEarningsAccumulatedLosses 2024-01-31 11748092 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2025-01-31 11748092 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2024-01-31 11748092 uk-bus:FRS102 2024-02-01 2025-01-31 11748092 uk-core:WithinOneYear 2025-01-31 11748092 uk-core:WithinOneYear 2024-01-31 11748092 uk-core:WithinOneYear 2025-01-31 11748092 uk-core:WithinOneYear 2024-01-31 11748092 uk-core:AfterOneYear 2025-01-31 11748092 uk-core:AfterOneYear 2024-01-31 11748092 2024-02-01 2025-01-31 11748092 uk-bus:AuditExempt-NoAccountantsReport 2024-02-01 2025-01-31 xbrli:pure iso4217:GBP xbrli:shares
 
 
 
Neurosurgery Solutions Limited
 
Directors' Report and Unaudited Financial Statements
 
for the financial year ended 31 January 2025
Neurosurgery Solutions Limited
DIRECTORS AND OTHER INFORMATION

 
Directors Dr Sanjeeva Jeyaretna
Mrs Anita Balakrishnan
 
 
Company Registration Number 11748092
 
 
Registered Office and Business Address 8 Fair View
Oxford
OX3 7EZ
United Kingdom
 
 
Accountants Capitax & Co (Tax Consultants) Ltd
Cuckoo Wharf
427 Lichfield Road
Birmingham
West Midlands
B6 7SS
GB



Neurosurgery Solutions Limited
DIRECTORS' REPORT
for the financial year ended 31 January 2025

 
The directors present their report and the unaudited financial statements for the financial year ended 31 January 2025.
 
Principal Activity

Specialist medical practice activities

Post-graduate education
     
Directors
The directors who served during the financial year are as follows:
     
Dr Sanjeeva Jeyaretna
Mrs Anita Balakrishnan
   
There were no changes in shareholdings between 31 January 2025 and the date of signing the financial statements.
     
In accordance with the Constitution, the directors retire by rotation and, being eligible, offer themselves for re-election.
     
Political Contributions
The company did not make any disclosable political donations in the current financial year.
     
Statement of Directors' Responsibilities
     
The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.
     

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law) including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland". Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:
▪ select suitable accounting policies and apply them consistently;
▪ make judgements and accounting estimates that are reasonable and prudent;
▪ prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
     
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
     
Special provisions relating to small companies
The above report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.
     
     
On behalf of the board
     
     
___________________________
Dr Sanjeeva Jeyaretna
Director
     
28 October 2025



Neurosurgery Solutions Limited
PROFIT AND LOSS ACCOUNT
for the financial year ended 31 January 2025
2025 2024
Notes £ £

Turnover 62,633 48,986
───────── ─────────
Gross profit 62,633 48,986
 
Administrative expenses (41,857) (44,146)
───────── ─────────
Profit before taxation 20,776 4,840
 
Tax on profit 4 (3,947) (920)
───────── ─────────
Profit for the financial year 16,829 3,920
───────── ─────────
Total comprehensive income 16,829 3,920
    ═════════   ═════════



Neurosurgery Solutions Limited
Company Registration Number: 11748092
BALANCE SHEET
as at 31 January 2025

2025 2024
Notes £ £
 
Current Assets
Debtors 5 5,688 3,080
Cash and cash equivalents 67,056 49,447
───────── ─────────
72,744 52,527
───────── ─────────
Creditors: amounts falling due within one year 6 (5,225) (2,537)
───────── ─────────
Net Current Assets 67,519 49,990
───────── ─────────
Total Assets less Current Liabilities 67,519 49,990
 
Creditors:
amounts falling due after more than one year 7 (17,624) (16,924)
───────── ─────────
Net Assets 49,895 33,066
═════════ ═════════
 
Capital and Reserves
Called up share capital - -
Retained earnings 49,895 33,066
───────── ─────────
Equity attributable to owners of the company 49,895 33,066
═════════ ═════════
 

These financial statements have been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.
           
For the financial year ended 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006.
           
The directors confirm that the members have not required the company to obtain an audit of its financial statements for the financial year in question in accordance with section 476 of the Companies Act 2006.
           
The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit and loss for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
           
Approved by the Board and authorised for issue on 28 October 2025 and signed on its behalf by
           
           
________________________________          
Dr Sanjeeva Jeyaretna          
Director          
           



Neurosurgery Solutions Limited
NOTES TO THE FINANCIAL STATEMENTS
for the financial year ended 31 January 2025

   
1. General Information
 

Neurosurgery Solutions Limited is a company limited by shares incorporated and registered in the United Kingdom. The registered number of the company is 11748092. The registered office of the company is 8 Fair View, Oxford, OX3 7EZ, United Kingdom which is also the principal place of business of the company. Specialist medical practice activities

Post-graduate education The financial statements have been presented in Pound (£) which is also the functional currency of the company.
         
2. Summary of Significant Accounting Policies
 
The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.
 
Statement of compliance

The financial statements of the company for the financial year ended 31 January 2025 have been prepared in accordance with the Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland (FRS 102) issued by the Financial Reporting Council and in accordance with the Companies Act 2006.

 
Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets.
 
Cash flow statement
The company has availed of the exemption in FRS 102 from the requirement to prepare a Statement of Cash Flows because it is classified as a small company.
 
Turnover
Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.
 
Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.
 
Borrowing costs
Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.
 
Trade and other creditors
Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.
 
Employee benefits
The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.
 
Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.
 
Foreign currencies
Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.
       
3. Employees
 
The average monthly number of employees, including directors, during the financial year was 0, (2024 - 0).
       
4. Tax on profit
  2025 2024
  £ £
Analysis of charge in the financial year
 
Current tax:
Corporation tax at 19.00% (2024 - 19.00%) 3,947 920
  ═════════ ═════════
       
5. Debtors 2025 2024
  £ £
 
Debtors 5,688 3,080
  ═════════ ═════════
       
6. Creditors 2025 2024
Amounts falling due within one year £ £
 
Bank overdrafts - 789
Taxation  (Note 8) 3,947 920
Accruals 1,278 828
  ───────── ─────────
  5,225 2,537
  ═════════ ═════════
       
7. Creditors 2025 2024
Amounts falling due after more than one year £ £
 
Directors' loan accounts 17,624 16,924
  ═════════ ═════════
 
       
8. Taxation 2025 2024
  £ £
 
Creditors:
Corporation tax 3,947 920
  ═════════ ═════════
       
9. Capital commitments
 
The company had no material capital commitments at the financial year-ended 31 January 2025.
   
10. Directors' advances, credits and guarantees
 
During the financial year, the company made no loan(s) to Director(s).
   
11. Post-Balance Sheet Events
 
There have been no significant events affecting the company since the financial year-end.